Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study
Open accessThe DOI matches its Crossref record; 54 of the 58 references it cites were found in a registry or an index.
Abstract
Background: Identifying reliable predictors of long-term weight loss (LTWL) could lead to improved weight management. Objective: To identify some predictors of LTWL. Design: The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin, intensive lifestyle intervention (ILS), or placebo. Its Outcomes Study (DPPOS) observed patients after the masked treatment phase ended. (ClinicalTrials.gov: NCT00004992 and NCT00038727). Setting: 27 DPP and DPPOS clinics. Participants: Of the 3234 randomly assigned participants, 1066 lost at least 5% of baseline weight in the first year and were followed for 15 years. Measurements: Treatment assignment, personal characteristics, and weight. Results: After 1 year, 289 (28.5%) participants in the metformin group, 640 (62.6%) in the ILS group, and 137 (13.4%) in the placebo group had lost at least 5% of their weight. After the masked treatment phase ended, the mean weight loss relative to baseline that was maintained between years 6 and 15 was 6.2% (95% CI, 5.2% to 7.2%) in the metformin group, 3.7% (CI, 3.1% to 4.4%) in the ILS group, and 2.8% (CI, 1.3% to 4.4%) in the placebo group. Independent predictors of LTWL included greater weight loss in the first year in all groups, older age and continued metformin use in the metformin group, older age and absence of either diabetes or a family history of diabetes in the ILS group, and higher fasting plasma glucose levels at baseline in the placebo group. Limitation: Post hoc analysis; examination of nonrandomized subsets of randomized groups after year 1. Conclusion: Among persons with weight loss of at least 5% after 1 year, those originally randomly assigned to metformin had the greatest loss during years 6 to 15. Older age and the amount of weight initially lost were the most consistent predictors of LTWL maintenance. Primary Funding Source: National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mean weight loss at 15-year follow-up was 6.2% (95% CI, 5.2%-7.2%) for metformin, 3.7% (95% CI, 3.1%-4.4%) for intensive lifestyle intervention, and 2.8% for placebo (95% CI, 1.3%-4.4%).93”
From Obesity Management in Adults: A Review (2023) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Doses of metformin greater than 1500 mg are associated with the greatest weight loss.93,94”
From Obesity Management in Adults: A Review (2023) · cites this paper as [93]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“12 weeks of treatment with licogliflozin led to a numerically greater reduction in liver lipid content, body weight (4.2 %) and HbA1c (1 %) compared to RCTs with sole SGLT2I treatment (Table 1) [161,163].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [161]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 3×
“Randomized controlled trials (RCTs) have shown efficacy of metformin, intensive lifestyle intervention (ILS), or both in preventing or delaying onset of T2D among high-risk persons with overweight and obesity (2, 3).”
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K.-Y. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,764 · cited 1×
“Second, we used GEE models (15, 16) to examine potential predictors of LTWL across all follow-up years.”
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Models for Longitudinal Data: A Generalized Estimating Equation Approach
Zeger, S. L., Liang, K.-Y., & Albert, P. S. (1988) · Biometrics · doi:10.2307/2531734 · Cited by 4,505 · cited 1×
“Second, we used GEE models (15, 16) to examine potential predictors of LTWL across all follow-up years.”
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287 · cited 1×
“Its beneficial effects include inhibition of gluconeogenesis with a consequent decrease in hepatic glucose output and increased insulin sensitivity, increased glucose utilization in the gut and enhanced insulin sensitivity in skeletal muscle (25, 26), and effects on the gut microbiota and the immune system (27).”
Research works printed but not linked: 1
- Diggle PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data. New York: Oxford University Press; 1994.
Cited by
Items 101–156 of 156
A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats
Seikrit, C., Lausberg, E., Buhl, E. M., Gáspár, R., Tábi, T., Heffer, M., Ducza, E., Sztojkov‐Ivanov, A., Seres, A. B., Szűcs, K. F., et al. (2021) · Cellular Physiology and Biochemistry · doi:10.33594/000000476 · Cited by 3
Metformin continuation post‐metabolic bariatric surgery and relapse of diabetes
Dicker, D., Pinto, D., & Reges, O. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15962 · Cited by 2
“18 However, this was not the case for those patients who had continued metformin after undergoing MBS in the current study.”
Obesity Pharmacotherapy: a Review of Current Practices and Future Directions
Schmitz, S. H., Tchang, B. G., & Shukla, A. P. (2023) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-023-00409-1 · Cited by 5
Clina, J. G., Sayer, R. D., Gorczyca, A. M., Das, S. K., Friedman, J. E., Chui, T. K., Roberts, S. B., & Hill, J. O. (2023) · Obesity Science & Practice · doi:10.1002/osp4.733 · Cited by 3
“9,14,44 For enrollment into the IWCR, much of initial recruitment was conducted through previous research participants from clinical trials related to obesity treat-ment.”
BackgroundCombined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 4
“Greater weight loss at year 1 was found to be an independent predictor of long-term weight loss in this cohort regardless of intervention [14].”
BackgroundWeight gain in pregnancy: can metformin steady the scales?
Adams, J. H., Poehlmann, J. R., Racine, J. L., Iruretagoyena, J. I., Eddy, A., Hoppe, K. K., Stewart, K. S., Rhoades, J. S., & Antony, K. M. (2022) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2022.2044775 · Cited by 3
Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01740 · Cited by 2
“Metformin is also an excellent option, given that she has prediabetes; it can lead to clinically signi fi cant weight loss (52) and has been shown to decrease the risk for progression to type 2 diabetes (53).”
Bianchi, C., Prato, S. D., Rothberg, A. E., & Nauck, M. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70674 · Cited by 3
Rebello, C. J., Greenway, F. L., Zhang, D., Johnson, W. D., Patterson, E., & Raum, W. J. (2022) · Obesity · doi:10.1002/oby.23384 · Cited by 3
Cucoreanu, C., Mureșan, X. M., Țigu, A. B., Nistor, M., Moldovan, R.-C., Pralea, I.-E., Iacobescu, M., Iuga, C. A., Constantinescu, C. S., Dindelegan, G., et al. (2024) · Reports — Medical Cases Images and Videos · doi:10.3390/reports7030074 · Cited by 3
“Different pathologies, such as hypothyroidism or Cushing syndrome, may cause weight gain and lower basal metabolism, leading to obesity [4,5].”
Katzmarzyk, P. T., Mire, E. F., Horswell, R. L., Chu, S. T., Zhang, D., Martin, C. K., Newton, R. L., Apolzan, J. W., Price‐Haywood, E. G., Fort, D. G., et al. (2024) · Obesity Science & Practice · doi:10.1002/osp4.70017 · Cited by 3
Self-citationBrown, J. C., Giobbie‐Hurder, A., Yung, R. L., Mayer, E. L., Tolaney, S. M., Partridge, A. H., & Ligibel, J. A. (2021) · Psycho-Oncology · doi:10.1002/pon.5817 · Cited by 2
Otsuka, Y., & Nakagami, T. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191911864 · Cited by 4
“Particularly, the most important determinant of risk reduction for incident diabetes in these trials was weight loss [8,9].”
BackgroundYunilaynen, O. A., Oleichik, I. V., Sizov, S. V., Баранов, П. А., & Starostina, E. G. (2021) · Obesity and metabolism · doi:10.14341/omet12684 · Cited by 2
Advising Patients on How to Achieve Long-Term Weight Loss
Katzel, L. I., & Sorkin, J. D. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0782 · Cited by 2
Joachim-Célestin, M., & Montgomery, S. (2024) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514241274696 · Cited by 4
An Updated Review on Repurposing of Metformin
Rikabi, H. A., Abdulla, D. A., & Mudawi, M. M. E. (2024) · Asian Journal of Pharmaceutical Research and Health Care · doi:10.4103/ajprhc.ajprhc_143_24 · Cited by 1
García-Ulloa, A. C., Pérez-Peralta, L., Urbina-Arronte, L. E., Cárdenas-Fragoso, J. L., Landa-Anell, M. V., Melgarejo-Hernández, M. A., Gil, V., Ponce‐de‐León, S., & Hernández-Jiménez, S. C. (2025) · Archives of Medical Research · doi:10.1016/j.arcmed.2025.103271 · Cited by 1
Koohshekan, B., Minaiyan, M., Hashemnia, M., & Aarabi, M. H. (2025) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_121_24 · Cited by 1
Metformin and incident osteoarthritis: Causal insights from a co-twin control study
Magnusson, K., Turkiewicz, A., Dell’Isola, A., Kiadaliri, A., & Englund, M. (2025) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2025.12.014 · Cited by 2
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Lactate as a Chemical Modification on Proteins and Metabolites
Xiao, S., Markhard, A. L., & Long, J. Z. (2026) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-051024-015746 · Cited by 2
Dapagliflozin-induced long-term and severe anorexia and weight loss: An extraordinary case
Cüre, E., Şirin, H., Cüre, M. C., & Sahin, D. (2021) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_785_19 · Cited by 1
Metformin Might Help Maintain Weight Loss Long Term
Dressler, D. D., Sfhm, & FACP., F. (2019) · Journal watch · doi:10.1056/nejm-jw.na48986
Advanced Metabolomics for Metabolic Syndrome/Metabolic Diseases
Sun, X., & Zhu, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-100596-5.22893-x
Han, J. J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737127674.793570321
John W. Apolzan, P., Elizabeth M. Venditti, P., Sharon L. Edelstein, S., Knowler, W. C., & Dana Dabelea, M. (2020) · Annals of Internal Medicine · doi:10.7326/l20-0029
Self-citationClinical Evaluation, Lifestyle, and Pharmacological Management of Obesity
Kolli, S., Tchang, B. G., Redmond, I. P., Barenbaum, S. R., & Saunders, K. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94953-2_14
Alekseev, V. A., KhKh, S., & Плотникова, О. А. (2022) · Voprosy Pitaniya · doi:10.33029/0042-8833-2022-91-4-6-18 · Cited by 2
GLP-1 RECEPTORIŲ AGONISTŲ REIKŠMĖ 2 TIPO CUKRINIU DIABETU SERGANČIŲ PACIENČIŲ SVORIO MAŽINIMUI
Viliušytė, M., Maleckas, A., & Malinauskas, M. (2024) · Health Sciences · doi:10.35988/sm-hs.2024.021
“Remiantis naujausiais duomenimis, antidiabetinis vaistas metforminas turi teigiamą poveikį tiek glikemijos kontrolei, tiek kūno svorio mažinimui keliais skirtingais mechanizmais [21].”
BackgroundInfluentialOverweight, understudied: The new need for weight loss modalities in CF patients
Schumacher, S., Harklau, N. M., Osterhaus, J., & Wright, B. A. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27011
Васильевна, Ц. О., Apartseva, N. E., Latyntseva, L. D., & Ryabikov, A. N. (2024) · Diabetes Mellitus · doi:10.14341/dm13189 · Cited by 1
The potential of metformin in weight loss
Григорьева, И. Н., & Nepomnyashchikh, D. L. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-530
Bhati, H., Mane, M., Gambhir, V., Samal, J. P., Swathi, V., Sohal, J., & Sood, S. (2024) · Seminars in Medical Writing and Education · doi:10.56294/mw2024524
Sticking Points About Weight Loss: Healthy or Harmful?
Tanofsky‐Kraff, M., Schvey, N. A., Pashby, R. O., & Burke, N. L. (2025) · Oxford University Press eBooks · doi:10.1093/oso/9780197752531.003.0005
Diabesidad: concepto e implicancias
Lahsen, R. (2025) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2025.08.010
“UU. ha mostrado que aquellos indivi-duos que disminuyen su peso en más de un 5% logran mantenerlo, en un seguimiento a 15 años, si se mantienen con el medicamento, no así los individuos de los grupos de cambios intensivos en el estilo de vida y el grupo placebo 33 .”
Targeting autophagy in metabolic diseases
Heidari, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00017-2
Obesity and musculoskeletal pain: possibilities of pharmacotherapy. A narrative overview
Karateev, A. E., & Zotkin, E. G. (2025) · Russian Journal of Pain · doi:10.17116/pain20252303173
Calderon, A., Parascando, J. A., Westfeldt, E. B., Prince, B. K., Oser, S. M., & Oser, T. K. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251399590
Farley, B., Radetich, E., D’Alessandro, J. S., & Bulaj, G. W. (2025) · Healthcare · doi:10.3390/healthcare13243220 · Cited by 2
“In patients with T2DM, up to a 5% total body weight loss can be observed [55].”
Allaire, B. T., Tjaden, A. H., Venditti, E. M., Apolzan, J. W., Dabelea, D., Delahanty, L. M., Edelstein, S. L., Hoskin, M. A., Temple, K. A., Wylie-Rosett, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13467993
Self-citationFerrannini, G., Pollock, C., Natali, A., Yavin, Y., Mahaffey, K. W., & Ferrannini, E. (2024) · Figshare · doi:10.6084/m9.figshare.26585985
Steven, C., Skylynn, T., Bardya, H., Megha, B., Helen, V., Lee, D., Entabi, F., & Pemminati, S. (2026) · Cureus · doi:10.7759/cureus.100704 · Cited by 2
“In the diabetes prevention program, about 29% of patients on metformin versus 13% on placebo lost at least 5% of baseline weight at one year, and about a quarter of metformin-treated patients maintained ≥5% loss at two years [30].”
Javadi, F., Nasli‐Esfahani, E., Hashempour, S., Montazer, M., Nouri, A., & Azadbakht, L. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01836-w · Cited by 1
“…use of first-line diabetes medications, par - ticularly metformin (which can promote weight stability or modest weight loss) and statins (which potently reduce LDL cholesterol), may have masked or neutralized any potential adverse effects of food addiction on these metabolic mark - ers [36, 37].”
McCleery, A., Haller, E., Kinlin, C., Wilson, K., Arnetz, B. B., Arnetz, J. E., Bohnsack, K. J., Burns, D., Dunbar, H., Johnson, A. M., et al. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251415549
Depression Associated with Other Medical Conditions
Sunzeri, F., & Sunzeri, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_12
Different weight loss strategies and their impact on fat and muscle tissue
Voznesenskaya, А. А., Rozhevskaya, E. E., & Shestakova, M. (2026) · Diabetes Mellitus · doi:10.14341/dm13372 · Cited by 1
Benefits and Costs of Treating Obesity Among Adults in Commercial Insurance Plans
Dall, T. M., Chen, F., Sapra, T., Ferguson, C., Hafida, S., Livingston, T., Moody, A., ElSayed, N. A., & Bannuru, R. R. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0006 · Cited by 1
“Comparable weight loss has been documented with the National Diabetes Prevention Program, despite different populations treated (16).”
Zoller, A. R., Athinarayanan, S. J., Tieghem, M. R. V., Adams, R. N., Roberts, C. G. P., Volek, J. S., Phinney, S. D., & McKenzie, A. L. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1839029
Marcelo, C., Esteban-Cantos, A., Jurado, F., Montejano, R., Gutiérrez-García, L., Grela, A. D. G., Martínez-Martín, P., Vidal, A. D., Buckley, R. D. M., López, C. M. O., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag489
“%) achieved in approximately 25%–30% of treated individuals, a threshold considered relevant in obesity management guidelines [12].”
Hartany, L. O. A., Alghorab, M. A., Alhomieed, M. F., Albalawi, R. S., Almowallad, A. A., Alsharif, A., Amin, A. S., Alamri, S. F., Aljabal, T. K., & Alkthiry, A. (2026) · Diabetology · doi:10.3390/diabetology7080156
“[47] RoB Some concerns Extended follow-up; post-randomization treatment changes may influence long-term estimates.”
Lac-Phe: An Exercise Hormone for Metabolic Regulation
Liu, Q., & Xu, Y. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-054717
Assal, H. S., Kamil, S. A., & Sciences, W. J. O. C. A. P. (2026) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750826600330
“…blood tests, as it is possible to reverse the effects of insulin resistance and prevent the onset of type 2 diabetes through lifestyle changes [11], medication, or sometimes a combination of both, and trying to implement a healthy diet in addition to practicing intermittent fasting, this…”
MCT6 is an intestinal Lac-Phe exporter required for metformin-associated weight loss
Xiao, S., Tung, A. S.-H., Spaas, J., Fu, S., Chen, X., Trinh, T. K., Moya-Garzón, M. D., Li, V. L., Cessna, H. T., Ito, K., et al. (2026) · Cell · doi:10.1016/j.cell.2026.09.058
Machine learning predicts weight change in a real-world digital health application
Glasbrenner, C., Lehmann, M., Höchsmann, C., Schirmann, F., & Koehler, K. (2026) · BMC Medicine · doi:10.1186/s12916-026-05320-x
“…the overall weight-analysis population and 69.7% of patients in the full-retention population (Additional file 1: Table S3) and was therefore imputed, which may have influenced model performance and feature importance rankings, given that age is typically a strong predictor of weight loss [44, 45].”
Influential
Metadata
- Authors
- Apolzan, J. W., Venditti, E. M., Edelstein, S. L., Knowler, W. C., Dabelea, D., Boyko, E. J., Pi-Sunyer, X., Kalyani, R. R., Franks, P. W., Srikanthan, P., Gadde, K. M., & for the Diabetes Prevention Program Research Group*
- Affiliations
- Pennington Biomedical Research Center (US)
- University of Pittsburgh Medical Center (US)
- George Washington University (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Colorado School of Public Health (US)
- VA Puget Sound Health Care System (US)
- Columbia University College of Physicians and Surgeons, New York, New York (X.P.)
- Johns Hopkins University (US)
- Lund University (SE)
- University of California, Los Angeles (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2019-05-21
- Volume
- 170
- Issue
- 10
- Pages
- 682-690
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC6829283
- OpenAlex
- W2942237347
- Semantic Scholar
- e07c5f43b88902ef91823985e00f3f37893ea00e
- Cited by
- 156
- References
- 58
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 21 · 2023: 28 · 2022: 22 · 2021: 21 · 2020: 16 · 2019: 9
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK048489)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- long-term weight loss, metformin, intensive lifestyle intervention, prediabetes, type 2 diabetes prevention, fasting blood glucose, age, family history of diabetes, Diabetes Prevention Program Outcomes Study
- MeSH terms
- Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Life Style, Male, Metformin, Middle Aged, United States, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.